MPM Oncology Impact Management »

Evommune shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Evommune (EVMN) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Evommune

Tip: Access up to 7 years of quarterly data

All positions including Evommune held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Evommune by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $1.9M 113k 17.12

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Madrigal Pharmaceuticals Common (MDGL)
Liquidia Corp Common (LQDA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Uniqure NV Common (QURE)
PTC Therapeutics Common (PTCT)
Syndax Pharmaceuticals Common (SNDX)
Dyne Therapeutics Common (DYN)
Tarsus Pharmaceuticals Common (TARS)
Stoke Therapeutics Common (STOK)
Alumis Common (ALMS)
Urogen Pharma Common (URGN)

View all positions for MPM Oncology Impact Management

Top funds holding Evommune

EQT Fund Management S.a r.l.
Pivotal bioVenture Partners Investment Advisor
Nan Fung Group Holdings
Rtw Investments
Marshall Wace
Eventide Asset Management
Sectoral Asset Management
Verition Fund Management
Standard Life Aberdeen
Velan Capital Investment Management
Vanguard Group
Octagon Capital Advisors
American Century Companies
Federated Investors
Dr. Jeffrey R. Jay, M.D.

View all funds holding Evommune